143 related articles for article (PubMed ID: 38367684)
21. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
[TBL] [Abstract][Full Text] [Related]
22. In vivo T cell depletion in miniature swine using the swine CD3 immunotoxin, pCD3-CRM9.
Huang CA; Yamada K; Murphy MC; Shimizu A; Colvin RB; Neville DM; Sachs DH
Transplantation; 1999 Sep; 68(6):855-60. PubMed ID: 10515387
[TBL] [Abstract][Full Text] [Related]
23. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
24. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
[TBL] [Abstract][Full Text] [Related]
25. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation.
Pan H; Lu HM; Hu WM; Tian BL; Liu XB; Zhang ZD; Mai G
Transplant Proc; 2007 Dec; 39(10):3452-4. PubMed ID: 18089405
[TBL] [Abstract][Full Text] [Related]
27. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
[TBL] [Abstract][Full Text] [Related]
28. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
29. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
Frankel AE; Zuckero SL; Mankin AA; Grable M; Mitchell K; Lee YJ; Neville DM; Woo JH
Curr Drug Targets; 2009 Feb; 10(2):104-9. PubMed ID: 19199905
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
32. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
33. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
34. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).
Woo JH; Bour SH; Dang T; Lee YJ; Park SK; Andreas E; Kang SH; Liu JS; Neville DM; Frankel AE
Cancer Immunol Immunother; 2008 Aug; 57(8):1225-39. PubMed ID: 18256829
[TBL] [Abstract][Full Text] [Related]
35. Neuropathy in miniature swine after administration of the mutant diphtheria toxin-based immunotoxin, pCD3-CRM9.
Gargollo P; Yamada K; Esnaola N; Fuchimoto Y; Newell KL; Sachs DH; Huang CA
Transplantation; 2001 Sep; 72(5):818-22. PubMed ID: 11571443
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
37. Novel TNF-related Apoptotic-inducing Ligand-based Immunotoxin for Therapeutic Targeting of CD25 Positive Leukemia.
Madhumathi J; Sridevi S; Verma RS
Target Oncol; 2016 Aug; 11(4):535-47. PubMed ID: 26984209
[TBL] [Abstract][Full Text] [Related]
38. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Lansigan F; Stearns DM; Foss F
Cancer Manag Res; 2010 Feb; 2():53-9. PubMed ID: 21188096
[TBL] [Abstract][Full Text] [Related]
39. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.
Zhang Y; Sun X; Huang M; Ke Y; Wang J; Liu X
Drug Des Devel Ther; 2015; 9():2947-59. PubMed ID: 26089644
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
